Join us for a discussion on how licensing and strategic collaborations, as well as proactive strengthening of your IP portfolio, enhance a company’s attractiveness to potential buyers. This complimentary program will feature key stakeholders—including in-house patent counsel, technology transfer officers, and transactional leaders from large pharmaceutical companies—all sharing their perspectives on how IP can make or break a growing company or an acquisition.
9:00-9:30 Breakfast
9:30-9:45 Welcome and Opening Remarks by Yifat Philip from ACC Biomed Forum and Finnegan partners Laura Masurovsky and Jeffrey Jacobstein
9:45-11:00 Licensing and Strategic Collaborations
• Invention harvesting and identifying inventors to expand the scope and value of your IP portfolio
• Collaborations and licensing with industry and university partners to monetize technologies while preserving opportunities to grow the core business
• Government regulations in multiple countries (e.g., NIH funding, Israeli Ministry of Health)
• When to file patent applications relative to development timeline in light of investor expectations
Moderator: Jeff Jacobstein
Panelists: Ariela Markel - Yissum Technology Transfer, Gerson Panitch – Partner at Finnegan, Keren Kanir – Horn & Co. Law Offices, Dr. Naomi Siew – VP of Ben Gurion University’s Tech Transfer, Natalie Vaisman – Insightec
11:00-11:15 Coffee and Networking Break
11:15-12:30 Increasing Corporate Valuation by Litigation Proofing Your IP Portfolio
• In-house role in proactively expanding and strengthening the value of your portfolio
• Identifying and preparing for patent challenges and understanding the financial implications
• Training scientists and company personnel on how to avoid the pitfalls of litigation
• Prelitigation due diligence
Moderator: Laura Masurovsky
Panelists: Asa Kling - Former Director of the Israel Patent Office and now at Naschitz Brandes Amir, David Schuz – Vyne, Sharon Hausdorff – Teva
Keynote Speech: Keren Leshem, CEO of OCON Healthcare
12:30 Lunch and Networking
